Jeff Schell is the President & CEO of TranS1, a company focused on crafting products that solve spinal pathologies leading to excellent patient outcomes with minimal tissue trauma. TranS1 recently conducted an economic analysis of its AxiaLIF which identified many benefits including cost savings. In this podcast, Jeff discusses the study and AxiaLIF.
Related Articles Read More >
Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
Here’s where Harvard’s engineering dean sees medtech research going
The cloud is transforming medtech: Amazon, Microsoft, Google, J&J, Philips and GE Healthcare leaders explain
